Histone H3 phosphorylation in GBM: A new rational to guide the use of kinase inhibitors in anti-GBM therapy

Theranostics

Volumn 5, Issue 1, 2015, Pages 12-22

  Pacaud, Romain ^a,b   Cheray, Mathilde ^a,b   Nadaradjane, Arulraj ^a,b   Vallette, François M ^a,b,c   Cartron, Pierre François ^a,b,c,d  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c UMR INSERM U892 CNRS 6299   (France)

^d Membre du Reseau Epigénétique du Canceropole Grand Ouest ^*  (France)

Author keywords

Apoptosis; Epigenetic; Glioma; Histone; Phosphorylation

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; AURORA B KINASE; BARASERTIB; ENZASTAURIN; HISTONE H3; JANUS KINASE 2; PROTEIN KINASE C; TEMOZOLOMIDE; 2-((3-((4-((5-(2-((3-FLUOROPHENYL)AMINO)-2-OXOETHYL)-1H-PYRAZOL-3-YL)AMINO)QUINAZOLIN-7-YL)OXY)PROPYL)(ETHYL)AMINO)ETHYL DIHYDROGEN PHOSPHATE; ANTINEOPLASTIC AGENT; DACARBAZINE; HISTONE; INDOLE DERIVATIVE; ORGANOPHOSPHATE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG SENSITIVITY; DRUG USE; FEMALE; GLIOBLASTOMA; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; MALE; OVERALL SURVIVAL; ANALOGS AND DERIVATIVES; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; PROTEIN PROCESSING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DACARBAZINE; FEMALE; GLIOBLASTOMA; HISTONES; HUMANS; INDOLES; MALE; MIDDLE AGED; ORGANOPHOSPHATES; PHOSPHORYLATION; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRAZOLES; PYRIMIDINES; QUINAZOLINES;

EID: 84924336977     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.8799     Document Type: Article

References (31)

1. Zheng C, Hayes J. Structures and interactions of the core histone tail domains. Biopolymers. 2003; 68: 539-46.
2. Luger K, Dechassa M, Tremethick D. New insights into nucleosome and chromatin structure: an ordered state or a disordered affair? Nat Rev Mol Cell Biol. 2012; 13: 436-47.
3. Rossetto D, Avvakumov N, Côté J. Histone phosphorylation: A chromatin modification involved in diverse nuclear events. Epigenetics. 2012; 7: 1098-108.
4. Sawicka A, Seiser C. Histone H3 phosphorylation-A versatile chromatin modification for different occasions. Biochimie. 2012; 94: 2193-201.
5. Baek S. When signaling kinases meet histones and histone modifiers in the nucleus. Mol Cell. 2011; 42: 274-84.
6. Dai J, Sultan S, Taylor S, Higgins J. The kinase haspin is required for mitotic histone H3 Thr 3 phosphorylation and normal metaphase chromosome alignment. Genes Dev. 2005; 19: 472-88.
7. Eswaran J, Patnaik D, Filippakopoulos P, Wang F, Stein R, Murray J, et al. Structure and functional characterization of the atypical human kinase haspin. Proc Natl Acad Sci U S A. 2009; 106: 20198-203.
8. Kang T, Park D, Choi Y, Kim K, Yoon H, Kim K. Mitotic histone H3 phosphorylation by vaccinia-related kinase 1 in mammalian cells. Mol Cell Biol. 2007; 27: 8533-46.
9. Metzger E, Imhof A, Patel D, Kahl P, Hoffmeyer K, Friedrichs N, et al. Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4. Nature. 2010; 464: 792-6.
10. Lee K, Song K. Basal c-Jun N-terminal kinases promote mitotic progression through histone H3 phosphorylation. cell cycle. 2008; 7: 216-21.
11. Goto H, Yasui Y, Nigg E, Inagaki M. Aurora-B phosphorylates Histone H3 at serine28 with regard to the mitotic chromosome condensation. Genes Cells. 2002; 7: 11-7.
12. Metzger E, Yin N, Wissmann M, Kunowska N, Fischer K, Friedrichs N, et al. Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation. Nat Cell Biol. 2008; 10: 53-60.
13. Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, et al. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell. 2012; 150: 685-96.
14. Preuss U, Landsberg G, Scheidtmann K. Novel mitosis-specific phosphorylation of histone H3 at Thr11 mediated by Dlk/ZIP kinase. Nucleic acids Res. 2003; 31: 878-85.
15. Shimada M, Niida H, Zineldeen D, Tagami H, Tanaka M, Saito H, et al. Chk1 is a histone H3 threonine 11 kinase that regulates DNA damage-induced transcriptional repression. Cell. 2008; 132: 221-32.
16. Hake S, Garcia B, Kauer M, Baker S, Shabanowitz J, Hunt D, et al. Serine 31 phosphorylation of histone variant H3.3 is specific to regions bordering centromeres in metaphase chromosomes. Proc Natl Acad Sci U S A. 2005; 102: 6344-9.
17. Dawson M, Bannister A, Göttgens B, Foster S, Bartke T, Green A, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature. 2009; 461: 819-22.
18. Hurd P, Bannister A, Halls K, Dawson M, Vermeulen M, Olsen J, et al. Phosphorylation of histone H3 Thr-45 is linked to apoptosis. J Biol Chem. 2009; 284: 16575-83.
19. van Beusechem V, Grill J, Mastenbroek D, Wickham T, Roelvink P, Haisma H, et al. Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. J Virol. 2002; 76: 2753-62.
20. Hegi M, Diserens A, Gorlia T, Hamou M, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 991-1003.
21. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000; 343: 1350-4.
22. Ma S, Rosen S. Enzastaurin. Curr Opin Oncol. 2007; 19: 590-3.
23. Wilkinson R, Odedra R, Heaton S, Wedge S, Keen N, Crafter C, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res. 2007; 13: 3682-8.
24. Ioannidis S, Lamb M, Wang T, Almeida L, Block M, Davies A, et al. Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol- 3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway. J Med Chem. 2011; 54: 262-76.
25. Galanis E, Buckner J. Enzastaurin in the treatment of recurrent glioblastoma: a promise that did not materialize. J Clin Oncol. 2010; 28: 1097-8.
26. Rampling R, Sanson M, Gorlia T, Lacombe D, Lai C, Gharib M, et al. A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054). Neuro Oncol. 2012; 14: 344-50.
27. Butowski N, Chang S, Lamborn K, Polley M, Pieper R, Costello J, et al. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol. 2011; 13: 1331-8.
28. Diaz R, Golbourn B, Shekarforoush M, Smith C, Rutka J. Aurora kinase B/C inhibition impairs malignant glioma growth in vivo. J Neurooncol. 2012; 108: 349-60.
29. McFarland B, Ma J, Langford C, Gillespie G, Yu H, Zheng Y, et al. Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol Cancer Ther. 2011; 10: 2384-93.
30. Wang F, Higgins J. Histone modifications and mitosis: countermarks, landmarks, and bookmarks. Trends Cell Biol. 2013; 23: 175-84.
31. Crosio C, Fimia G, Loury R, Kimura M, Okano Y, Zhou H, et al. Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol. 2002; 22: 874-85.